Press Releases

Augurex Announces UKCA Authorization for SPINEstat™, Expanding Access of a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis to Great Britain

SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing diagnostic challenges associated with axSpA. AxSpA is an inflammatory autoimmune condition of the spine, often misdiagnosed as persistent lower back pain for 7–10 years before accurate detection. Earlier diagnosis is essential to prevent irreversible spinal damage and to improve outcomes. SPINEstat™ offers physicians an objective, clinically validated biomarker to support early and accurate axSpA diagnosis, marking a major advancement in autoimmune diagnostics across the UK.

Ambience Healthcare’s AI Platform for Documentation, CDI, and Coding Now Available in Microsoft Azure Marketplace

Cleveland Diagnostics Announces Landmark Longitudinal Study Published in Urology

Predictive Power of IsoPSA Is Sustained For Over Two Years; Data Strengthens Evidence for IsoPSA’s Accuracy in Prostate Cancer Detection & Patient Risk Assessment

What the Future Holds for Hospital-Acquired Infections Diagnostics and Patient Care

Hospital-acquired infections (HAIs) remain a major concern in healthcare, causing significant morbidity, mortality, and increased hospital costs. Despite advancements in infection control, HAIs continue to affect millions of patients annually, often due to antibiotic-resistant pathogens.

Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis

SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune condition impacting the spine, axSpA often goes undiagnosed, mistaken for persistent lower back pain for 7-10 years before an accurate diagnosis. There is an urgent need to decrease the diagnostic delay for axSpA. If untreated, axSpA is a highly debilitating disease that causes irreversible spinal fusion leading to reduced mobility and quality of life. It can strike at any age, but typically begins before age 45, during the most productive years of a person’s life.

Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development

CluePoints’ Technology Named as Finalist in 2025 Citeline Awards

CluePoints, provider of leading statistical and AI-driven software solutions, has been named as a finalist in the ‘Innovative Clinical Trial Solutions’ category at the 2025 Citeline Awards.

VieCure Integrates NCCN Content into Leading Technology Platform for Community Oncology Care

VieCure is making thousands of the most commonly used NCCN Chemotherapy Order Templates available on its Halo Intelligence Platform

Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem

Oxford Nanopore Technologies announced the expansion of its Compatible Products Program. New participating companies include: 10x Genomics, Agilent Technologies, Asuragen, Day Zero Diagnostics, Hamilton Robotics, NEB, Opentrons, Pathosense, and Thermo Fisher Scientific.

Phastar Secures Finalist Spot at 2025 Citeline Awards

Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.

ELRIG Appoints Dr Del Trezise as Chair

MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer

A groundbreaking study published in the journal Clinical Cancer Research validates previous findings that the PROSTOX ultra test can predict long-term side effects from radiation therapy for prostate cancer, prior to starting treatment. Led by researchers at UCLA’s Department of Radiation Oncology, the study confirms the effectiveness of PROSTOX ultra, the first test capable of predicting long-term radiation side effects based on a patient’s unique genetic profile. The findings reinforce that radiation toxicity is a biologically unique response for each patient, underscoring the potential to personalize and improve cancer treatment using genetics.

Clearwater Publishes Cyber Risk Benchmark Trend Report for Healthcare Vulnerability Management

CluePoints Appoints Usama Dar as Chief Product and Technology Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has today announced Usama Dar as its new Chief Product and Technology Officer.

Association for Molecular Pathology Celebrates U.S. District Court’s Decision to Vacate FDA Rule on Laboratory-Developed Test Procedure Regulation

AMP announced a favorable ruling in its lawsuit against the U.S. FDA over the regulation of laboratory-developed test procedures.

Andaman7 Seeks $5m to Continue Investment in Pioneering Technology

Andaman7, the platform transforming healthcare communications and bridging the gap between patients and researchers, is seeking investment to reach the next milestones in its ground-breaking journey.

Baylor Genetics Presents New Data on Genetic and Functional Testing to Diagnose Mitochondrial Disorders at 2025 ACMG Annual Clinical Genetics Meeting

Baylor Genetics Presents New Data on Genetic and Functional Testing to Diagnose Mitochondrial Disorders at 2025 ACMG Annual Clinical Genetics Meeting

Novartis Strengthens Cardiovascular Portfolio with $3.08 Billion Anthos Therapeutics Acquisition

Anthos Therapeutics, Inc., a business that produces abelacimab (full human monoclonal antibody), a late-stage medication being developed to prevent stroke and systemic embolism in patients with atrial fibrillation, has agreed to be acquired by Novartis. Upon concluding the deal, Novartis will pay $925 million upfront, subject to certain usual adjustments. If certain sales and regulatory milestones are met, Novartis may also pay an additional $2.15 billion.

Coronado Research Announce the Appointment of Gary Lyons as EVP Medical Affairs

Coronado Research has appointed Gary Lyons as EVP Medical Affairs. Gary is a seasoned senior Medical Affairs leader with extensive strategic and operational implementation experience across the industry and product lifecycle.

Proscia Raises $50M To Advance AI-Driven Pathology And Deliver The Future Of Precision Medicine

Funding led by global software investor Insight Partners comes as the surge in cancer cases compounds the impact of the shrinking pathologist workforce.